

Mixed Inbred FVB;B6 Background Strain Attenuates Kidney Disease and Improves Survival of $Gne^{M712T/M712T}$ Mice

Yadira Valles-Ayoub^{1,2}, Arman Haghghatgoo^{1,2}, Chai Saechao¹, Zeshan Khokher^{1,2}, Christopher Creencia³, Oscar Scremin^{2,4}, Gregory Lawson, DVM^{2,5}, Babak Darvish² and Daniel Darvish^{1,2*}

¹HIBM Research Group, Reseda, CA

²VA Greater Los Angeles (VA-GLA/UCLA), Los Angeles, CA

³Tissue Procurement Core Laboratory, Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, CA

⁴Molecular, Cellular & Integrative Physiology IDP, UCLA, Los Angeles, CA

⁵Division of Laboratory Animal Medicine, UCLA, Los Angeles, CA

Abstract

Recessive form of Hereditary Inclusion Body Myopathy (HIBM, IBM2, MIM:600737) is an adult onset muscle wasting disorders caused by hypomorphic GNE, the rate-limiting enzyme of sialic acid (Sia) biosynthesis. Unlike human patients, mice bearing the $Gne^{M712T/M712T}$ genotype in C57BL/6 background strain suffer severe glomerular hematuria, incomplete podocyte development, and do not survive beyond the first few days of life. We crossed heterozygous mice ($Gne^{M712T/+}$) of B6 strain with FVB strain mice. In mixed inbred FVB;B6 background, the homozygous mice show attenuated glomerular disease and survive longer (mean survival 22 ± 13 weeks, $n=26$). Paradoxically, the homozygous mice showed increased total Sia levels in serum (2x control), and Neu5Ac:Neu5Gc ratios are slightly shifted towards Neu5Ac in serum and towards Neu5Gc in muscle tissue. Increase in serum Sia levels may be caused by altered glomerular filtration. This paradoxical increase in serum Sia may contribute to Sia pools of muscle, and exert a potential beneficial effect. In summary, the background strain of mouse model can significantly affect the disease phenotype.

Keywords: Muscular dystrophy; Nonaka; Distal myopathy with rimmed vacuoles (DMRV); Sialylation; Glycosylation

Introduction

Inclusion Body Myositis & Myopathies (IBMs) are a group of adult-onset slowly progressive muscle disorders, often leading to severe disability [1]. The most common of the hereditary forms of IBMs is the autosomal recessive Hereditary Inclusion Body Myopathy (HIBM, IBM2, MIM:600737, DMRV, MIM:605820) or GNE myopathy. At the cellular level, histological phenotype of affected myofibers in HIBM/DMRV reveals presence of rimmed autophagic-like vacuoles and inclusion bodies with filamentous components containing β -amyloid, lysosomal proteins, tau and presenilin [2]. HIBM/DMRV is caused by mutations in the GNE gene (MIM:603824) [3-5]. GNE encodes for the bifunctional enzyme UDP-N-Acetylglucosamine 2-Epimerase/N-Acetylmannosamine Kinase (GNE/MNK), which is the rate-limiting enzyme for sialic acid (Sia) biosynthesis [6]. HIBM/DMRV mutations lead to hypomorphic GNE/MNK enzyme [7,8]. GNE expression in mammalian cells is ubiquitous, with higher levels in placenta, liver, secretory organs, mucosa, and some cancer cells [9]. It remains unknown why clinical symptoms and pathology in HIBM/DMRV patients are limited to skeletal muscle tissue. To date, two mouse models have been produced for HIBM/DMRV:

- 1) Gne^{M712T} knock-in mouse model bearing the most common founder genotype of HIBM/DMRV patients, GNE p.M712T. This model mouse was produced by homologous recombination, and Gne is driven by the endogenous promoter. In C57BL/6 mouse strain, the $Gne^{M712T/M712T}$ mice do not survive beyond early postnatal days due to severe kidney disease, glomerular hematuria, hyposialylation of podocalyxin, and seemingly incomplete development of podocyte foot processes. Additionally, N-Acetylmannosamine (ManNAc) is salutary to the kidney disease and significantly improves survival [10].
- 2) Transgenic mice expressing human GNE with p.D176V mutation, in Gne-null background. The GNE transgene is driven by the strong mammalian promoter CAG, which is a hybrid of chicken beta-actin and CMV promoters [11,12].

After the age of 40 weeks, this mouse exhibits myopathy similar to the HIBM/DMRV patients. Prophylactic administration of N-Acetylmannosamine, N-acetylneuraminase, and Sialyllactose precludes the development of myopathic phenotype in this model [13].

In this study, we crossed the B6 heterozygous Gne^{M712T} mice with FVB mice to produce a mixed inbred B6;FVB strain, and to evaluate the effect of the Gne^{M712T} mutation in different inbred mouse strains. Crossing with FVB background strain was chosen because FVB mice have vigorous reproductive performance with large litters [14], and often show modified genetic disease phenotype compared to B6 [15-17].

Methods

Animals

FVB/NJ mice were obtained from the Jackson Laboratories, and Gne^{M712T} mouse was provided by HIBM Research Group. Breeding were performed at Greater Los Angeles VA Healthcare System, Veterinary medical unit. Animals had access ad libitum to water and Mouse Diet 5015 chow (PMI Nutrition International, LLC, Brentwood, MO) or Teklad Rodent Diet (Harlan Laboratories, Indianapolis, IN). The B6- $Gne^{M712T/+}$ mice were crossed with FVB/NJ strain mice, and the N1 generation were further crossed to produce mixed inbred homozygous

***Corresponding author:** Daniel Darvish, MD HIBM Research Group, 18341 Sherman Way #201A, Reseda, CA 91335, Tel: 818-789-1033 x3; Fax: 818-741-3727; E-mail: ddarvish@hibm.org

Received March 03, 2012; **Accepted** March 26, 2012; **Published** April 01, 2012

Citation: Valles-Ayoub Y, Haghghatgoo A, Saechao C, Khokher Z, Creencia C, et al. (2012) Mixed Inbred FVB;B6 Background Strain Attenuates Kidney Disease and Improves Survival of $Gne^{M712T/M712T}$ Mice. Mol Biol 1:104. doi:10.4172/2168-9547.1000104

Copyright: © 2012 Valles-Ayoub Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

mice (FVB;B6-*Gne*^{M712T/M712T}). Studies were conducted in accordance with the guidelines set forth by the Greater Los Angeles VA Healthcare System Institutional Animal Care and Use Committee and by NIH's Guidelines for the Care and Use of Laboratory Animals.

Molecular analysis

Mouse genotyping was performed on either or both tail genomic DNA and cDNA isolated from skeletal muscle, liver, kidneys, and brain using standard protocols. Total RNA was isolated from murine tissues using the TRIZOL reagent (Invitrogen, Carlsbad, California, USA), and cDNA prepared using the SuperScript III system (Invitrogen). Multiplex PCR based genotyping was performed across *Gne* exon 12 on genomic DNA as template, using three custom designed primer sets (Figure 1). For amplification of cDNA template, we used the custom designed primer set m*Gne*-E11F and m*Gne*-E12R, using PuReTaq Ready-To-Go PCR beads (GE HealthCare, Waukesha, Wisconsin, USA) or REDTaq and appropriate buffer (Sigma-Aldrich, St. Louis, Missouri, USA), by standard PCR conditions. Sequencing was performed using DYEnamic ET kit (GE Healthcare) on ABI 377-96 Prism (Applied Biosystems, Foster City, CA, USA).

Sialic acid analysis

Serum and tissue sialic acid analysis was performed at UCSD Glycotechnology Core Resource using HPLC-DMB method [18]. Sample is dissolved in a final concentration of 2 M HOAc and heated to 80°C for 3 hours to release sialic acids. The released sialic acids are collected by ultra-filtration through a 3,000 NMWCO filter and derivatized with 1,2-diamino-4,5-methylenedioxybenzene dihydrochloride (DMB). The fluorescent sialic acid derivatives are analyzed by reverse-phase HPLC with on-line fluorescence detection.

Serum chemistry

Creatine Kinase (CK) and Blood Urea Nitrogen (BUN) was analyzed by UCLA Division of Laboratory Animal Medicine (DLAM).

Behavioral analysis

Motor function testing using Rotarod treadmill, Grip strength analysis, and open field was performed using standard methods. The Rotarod treadmill (Ugo-Basile, Italy) instrument consists of a rotating rod, elevated so as to discourage the animals from stepping




Figure 1: Genomic and cDNA analysis. A) Genotyping design showing *Gne* exon 12. B) Genotyping of *Gne* locus. Bilateral PCR amplification of specific alleles (Bi-PASA) was used for *Gne* locus using primers F (5'ctggaactgcttgggact), R (5'attgccttcgcagaaacactga), inner primers requiring gc rich tails (underlined), wildtype allele WP (5'ggcgccggcgccgcagccagcat), and mutant allele primer MP (5'ggcgccggcgctgtagtcagaaccg). C) Muscle cDNA sequencing of FVB;B6-*Gne*^{M712T/M712T} mouse showing homozygous M712T (atg>acg).




Figure 2: Kidneys of homozygous mouse at age of 40 weeks and age matched heterozygous and wildtype control littermates. Kidneys of homozygous M712T mice are grossly smaller and granular, and histologically show severe membranous glomerulonephritis and loss of Bowman's space (White Arrow).




Figure 3: Motor function analysis did not result in statistically significant difference between homozygous, heterozygous, or wildtype mice at various age groups.

down. Mice were first conditioned to the device by running them at progressive speeds up to 40 rpm during 10 minutes for three sessions, separated by 30 minutes intervals during the first day of exposure to the instrument. During the second day the speed was incremented from 40 rpm at 5 rpm increments every 5 minutes until they fall from the treadmill. Three sessions was performed for each animal, separated by 30 min intervals. The average running time was recorded for each animal. For Grip strength analysis, a digital force gauge DFIS 10 (John Chatillon & Sons, Inc, Greensboro, NC) instrument is fitted with a bar that the animals grasp. As the mice are moved away from the bar by manually pulling them from the body, the force exerted on the instrument is continuously measured and the maximal force developed at the time when the animal releases the grip on the bar is recorded as the grip strength. The animals were a flat surface and their bodies will be at zero angle with the direction of the pulling force. The average of three attempts, separated by three minutes, was recorded for each animal. For open-field activity analysis, each mouse was placed in circular open field chambers of 25 cm diameter under low level illumination for a duration of 20 minutes. This is done to maximize exploratory activity, which is normally inhibited in rodents by daylight or bright illumination, and to eliminate unwanted visual clues from the surrounding environment. The animal movements was recorded with a video tracking and motion analysis system, which consists of a Sony CCD video camera (sensitive to the wavelength of light used), Targa M16 Plus video digitizing board on a Microcomputer, and Ethovision software (Noldus, Inc, The Netherlands). Tracking was performed at a rate of 1 Hz during the entire 20 min session and stored in memory. Movement analysis included total distance traveled, habituation (decay slopes of distance traveled as a function of time), average speed, and maximum speed over 5, and 20 sec intervals, average heading, turn angle and angular velocity, turn bias, and sinuosity.

Statistical methods

Means were compared using the parametric one way analysis of variance model and post hoc t tests were computed under this model. Medians were compared using the corresponding non-parametric Kruskal-Wallis method. P values <0.10 were considered significant.

Results

We produced the mixed inbred B6;FVB background mice bearing the most common mutation seen in HIBM patients, the Middle East founder $Gne:p.M712T$ (atg>acg) [3]. In B6;FVB strain, the number of homozygous pups surviving to weaning age is improved, but remains below Mendelian expected rate of 25% from heterozygous-heterozygous mating. Of 59 litters, totaling 409 mice, pups surviving to weaning age included 56% wildtype, 38% heterozygous, and 6% homozygous. The surviving homozygous mice (mean survival 22 ± 13 weeks, n=26) invariably show moderate to severe kidney disease (Figure 2).

As previously reported, the homozygous pups in B6 background are physically much smaller than their heterozygous and wildtype littermates [10]. However, in mixed inbred FVB;B6 strain, the homozygous are similar in size (length and weight) compared to their littermates. Motor strength/endurance testing (i.e. Rotarod treadmill and grip strength), exercise induced creatine kinase elevation, and open-field for gross locomotor activity level, did not show statistically significant difference in homozygous and littermate controls (Figure 3 and Figure 4).

Serum was analyzed for Blood Urea Nitrogen (BUN), which showed 2X higher in homozygous mice (45.5 ± 18.6 mg/dL, n=9,

reference/control range 12-28). Unlike humans, who only produce N-Acetylneuraminic acid (Neu5Ac), rodents produce both Neu5Ac N-glycolylneuraminic acid (Neu5Gc) [19]. The homozygous mice show altered Sia profile, with reduced Neu5Ac fraction in muscle, and higher Neu5Ac fraction in serum (Figure 5). Higher total serum Sia levels may be the result of chronic renal failure and reduced total serum protein [20].

Discussion

This study describes follow up data pertinent to the model #1 described above [10]. This work demonstrates the variable phenotype severity seen in two commonly available inbred mouse strains. Because the background mouse strain influences the severity of renal disease caused by $Gne^{M712T/M712T}$ genotype, and since human HIBM patients with $GNE^{M712T/M712T}$ do not suffer from kidney disease, we believe the efficiency of the sialic biosynthetic pathway in different organs is dependent on other background genes. Additionally, the paradoxical high serum Sia levels in this mouse model may contribute to delayed onset of muscle disease because the myofibers may benefit from higher serum Sia levels [13]. The reason for altered Neu5Ac:Neu5Gc ratio seen in skeletal muscles of this mouse model can be attributed to higher levels of Neu5Gc in muscle and higher levels of Neu5Ac in serum, however significance of the altered Neu5Ac:Neu5Gc ratios to human disease remains unclear.

We did not examine the muscle histologically in this inbred strain because motor function and activity (rotarod, grip strength, open field activity) showed significant variability even within the same age matched genotype group, and thus did not show statistically significance difference between the genotype groups at any age.




Figure 4: Exercise induced CK elevation did not result in statistically significant difference between homozygous, heterozygous, or wildtype mice.




Figure 5: Sia profile. W=Wildtype, H=Heterozygous, M=Homozygous $Gne:p.M712T$. Homozygous mice show altered Sia profile. In muscle, ratio of Neu5Gc/Neu5Ac is increased. Serum Sia is 1.5 – 2X control littermates (n=4 each genotype group, p<0.05).

Since skeletal muscle is the only organ clinically affected in HIBM/DMRV human patients [21-25], our future direction for this project includes production of a hypomorphic Gne mouse model that shows significant pathology only in skeletal muscles. Our future strategies to produce such model include development of congenic FVB strain, and skeletal muscle specific Gne knock-out mouse.

In Summary, the background strain of mouse model can significantly affect the disease phenotype, and producing mouse models of human disease in several inbred background strains may prove useful in developing an optimal model that most closely resembles the human disorder.

Acknowledgement

We thank Dr. Jeffrey Gornbein (UCLA) for assistance with statistical analysis, Juan Orozco and Jennifer Kay for assistance with mouse colony management, rorod treadmill, open-field, and grip-strength evaluation. Funding was provided by Advancement of Research for Myopathies (A.R.M.) and David and Laura Merage Foundation.

References

1. Needham M, Mastaglia FL, Garlepp MJ (2007) Genetics of inclusion-body myositis. *Muscle Nerve* 35: 549-561.
2. Askanas V, Engel WK, Yang CC, Alvarez RB, Lee VM, et al. (1998) Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. *Am J Pathol* 152: 889-895.
3. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, et al. (2001) The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. *Nat Genet* 29: 83-87.
4. Darvish D, Vahedifar P, Huo Y (2002) Four novel mutations associated with autosomal recessive inclusion body myopathy (MIM: 600737). *Mol Genet Metab* 77: 252-256.
5. Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, et al. (2002) Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. *Neurology* 59: 1689-1693.
6. Hinderlich S, Stasche R, Zeitler R, Reutter W (1997) A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. *J Biol Chem* 272: 24313-24318.
7. Noguchi S, Keira Y, Murayama K, Ogawa M, Fujita M, et al. (2004) Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. *J Biol Chem* 279: 11402-11407.
8. Sparks SE, Ciccone C, Lalor M, Orvisky E, Klootwijk R, et al. Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy. *Glycobiology* 15: 1102-1110.
9. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, et al. Large-scale analysis of the human and mouse transcriptomes. *Proc Natl Acad Sci USA* 99: 4465-4470.
10. Galeano B, Klootwijk R, Manoli I, Sun M, Ciccone C, et al. (2007) Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. *J Clin Invest* 117: 1585-1594.
11. Malicdan MC, Noguchi S, Nonaka I, Hayashi YK, Nishino I, et al. (2007) A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. *Hum Mol Genet* 16: 2669-2682.
12. Alexopoulou AN, Couchman JR, Whiteford JR (2008) The CMV early enhancer/chicken beta actin (CAG) promoter can be used to drive transgene expression during the differentiation of murine embryonic stem cells into vascular progenitors. *BMC Cell Biol* 9: 2.
13. Malicdan MCV, Noguchi S, Hayashi YK, Nonaka I, Nishino I, et al. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. *Nat Med* 15: 690-695.
14. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, et al. (1991) FVB/N: an inbred mouse strain preferable for transgenic analyses. *Proc Natl Acad Sci U S A* 88: 2065-2069.
15. Hadano S, Yoshii Y, Otomo A, Kunita R, Suzuki-Utsunomiya K, et al. (2010) Genetic background and gender effects on gross phenotypes in congenic lines of ALS2/alsin-deficient mice. *Neurosci Res* 68: 131-136.
16. Colombo C, Haluzik M, Cutson JJ, Dietz KR, Marcus-Samuels B, et al. (2002) Opposite effects of background genotype on muscle and liver insulin sensitivity of lipodystrophic mice. Role of triglyceride clearance. *J Biol Chem* 278: 3992-3999.
17. Menalled L, El-Khodori BF, Patry M, Suárez-Fariñas M, Orenstein SJ, et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. *Neurobiol Dis* 35: 319-336.
18. Hara S, Takemori Y, Yamaguchi M, Nakamura M, Ohkura Y (1987) Fluorometric high-performance liquid chromatography of N-acetyl- and N-glycolylneuraminic acids and its application to their microdetermination in human and animal sera, glycoproteins, and glycolipids. *Anal Biochem* 164: 138-145.
19. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. *Proc Natl Acad Sci USA* 95: 11751-11756.
20. Ozben T (1991) Elevated serum and urine sialic acid levels in renal diseases. *Ann Clin Biochem* 28: 44-48.
21. Nonaka I, Sunohara N, Ishiura S, Satoyoshi E (1981) Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. *J Neurol Sci* 51: 141-155.
22. Argov Z, Yarom R (1984) "Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews. *J Neurol Sci* 64: 33-43.
23. Massa R, Weller B, Karpati G, Shoubridge E, Carpenter S (1991) Familial inclusion body myositis among Kurdish-Iranian Jews. *Arch Neurol* 48: 519-522.
24. Sadeh M, Gadot N, Hadar H, Ben David E (1993) Vacuolar myopathy sparing the quadriceps. *Brain* 116: 217-232.
25. Sparks S, Rakocevic G, Joe G, Manoli I, Shrader J, et al. (2007) Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. *BMC Neurol* 7: 3.